Exome sequencing identified rare recurrent copy number variants and hereditary breast cancer susceptibility.
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
27
03
2023
accepted:
27
07
2023
revised:
24
08
2023
medline:
28
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect gene dosage. They are known to be causal or underlie predisposition to various diseases. However, the role of CNVs in inherited breast cancer susceptibility has not been thoroughly investigated. To address this, we performed whole-exome sequencing based analysis of rare CNVs in 98 high-risk Northern Finnish breast cancer cases. After filtering, selected candidate alleles were validated and characterized with a combination of orthogonal methods, including PCR-based approaches, optical genome mapping and long-read sequencing. This revealed three recurrent alterations: a 31 kb deletion co-occurring with a retrotransposon insertion (delins) in RAD52, a 13.4 kb deletion in HSD17B14 and a 64 kb partial duplication of RAD51C. Notably, all these genes encode proteins involved in pathways previously identified as essential for breast cancer development. Variants were genotyped in geographically matched cases and controls (altogether 278 hereditary and 1983 unselected breast cancer cases, and 1229 controls). The RAD52 delins and HSD17B14 deletion both showed significant enrichment among cases with indications of hereditary disease susceptibility. RAD52 delins was identified in 7/278 cases (2.5%, P = 0.034, OR = 2.86, 95% CI = 1.10-7.45) and HSD17B14 deletion in 8/278 cases (2.9%, P = 0.014, OR = 3.28, 95% CI = 1.31-8.23), the frequency of both variants in the controls being 11/1229 (0.9%). This suggests a role for RAD52 and HSD17B14 in hereditary breast cancer susceptibility. The RAD51C duplication was very rare, identified only in 2/278 of hereditary cases and 2/1229 controls (P = 0.157, OR = 4.45, 95% CI = 0.62-31.70). The identification of recurrent CNVs in these genes, and especially the relatively high frequency of RAD52 and HSD17B14 alterations in the Finnish population, highlights the importance of studying CNVs alongside single nucleotide variants when searching for genetic factors underlying hereditary disease predisposition.
Identifiants
pubmed: 37578974
doi: 10.1371/journal.pgen.1010889
pii: PGENETICS-D-23-00342
pmc: PMC10449128
doi:
Substances chimiques
HSD17B14 protein, human
EC 1.1.-
17-Hydroxysteroid Dehydrogenases
EC 1.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010889Informations de copyright
Copyright: © 2023 Kumpula et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Am J Hum Genet. 2008 Dec;83(6):787-94
pubmed: 19061986
Cell Rep. 2022 Nov 15;41(7):111672
pubmed: 36384125
Cell Metab. 2020 Jun 2;31(6):1154-1172.e9
pubmed: 32492394
Nat Commun. 2019 Mar 4;10(1):1025
pubmed: 30833565
Int J Cancer. 2023 Feb 1;152(3):429-435
pubmed: 36161273
Clin Cancer Res. 2017 Jun 1;23(11):2617-2629
pubmed: 28572256
Commun Biol. 2022 Jan 18;5(1):65
pubmed: 35042965
Bioinformatics. 2012 Nov 1;28(21):2747-54
pubmed: 22942019
PLoS Genet. 2012;8(6):e1002734
pubmed: 22737080
Nature. 2010 Apr 1;464(7289):704-12
pubmed: 19812545
Nature. 2007 Mar 15;446(7133):316-9
pubmed: 17287723
Nat Genet. 1997 Nov;17(3):341-5
pubmed: 9354803
Breast Cancer Res. 2012 Feb 07;14(1):R24
pubmed: 22314128
Genes (Basel). 2018 Dec 13;9(12):
pubmed: 30551670
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):686-91
pubmed: 21148102
Annu Rev Genomics Hum Genet. 2009;10:451-81
pubmed: 19715442
J Natl Cancer Inst. 2018 Aug 1;110(8):855-862
pubmed: 30099541
Eur J Cancer. 2021 Jan;143:46-51
pubmed: 33279852
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Annu Rev Pathol. 2020 Jan 24;15:51-70
pubmed: 31977294
Hum Mutat. 2016 Jun;37(6):564-9
pubmed: 26931183
Am J Hum Genet. 1998 Jun;62(6):1544-8
pubmed: 9585608
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS Genet. 2016 Jan 28;12(1):e1005816
pubmed: 26820313
Nat Rev Genet. 2015 Mar;16(3):172-83
pubmed: 25645873
Nat Rev Genet. 2006 Feb;7(2):85-97
pubmed: 16418744
Oncotarget. 2017 May 2;8(18):30552-30562
pubmed: 28430630
Oncogene. 2013 Jul 25;32(30):3552-8
pubmed: 22964643
Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:7-9
pubmed: 20711663
Am J Hum Genet. 2021 Aug 5;108(8):1409-1422
pubmed: 34237280
Breast Cancer Res Treat. 2009 May;115(2):315-23
pubmed: 18546071
Trends Cell Biol. 2016 Jan;26(1):52-64
pubmed: 26437586
N Engl J Med. 2010 May 20;362(20):1909-19
pubmed: 20484397
Nucleic Acids Res. 2014 Jan;42(Database issue):D986-92
pubmed: 24174537
J Pathol. 2021 Oct;255(2):202-211
pubmed: 34231212
Biometrics. 1992 Jun;48(2):361-72
pubmed: 1637966
Genome Biol. 2014 Jun 02;15(6):R80
pubmed: 24958239
Clin Genet. 2018 Mar;93(3):595-602
pubmed: 28802053
Genet Med. 2017 Jun;19(6):667-675
pubmed: 28574513
Science. 2014 Mar 28;343(6178):1466-70
pubmed: 24675953
J Natl Cancer Inst. 2020 Dec 14;112(12):1242-1250
pubmed: 32107557
Genes Dev. 2018 Apr 1;32(7-8):524-536
pubmed: 29636371
Clin Chim Acta. 2018 May;480:173-179
pubmed: 29458049
J Natl Cancer Inst. 2019 Dec 1;111(12):1332-1338
pubmed: 30949688
Mol Oncol. 2020 Jun;14(6):1124-1133
pubmed: 32175645
Curr Opin Genet Dev. 2010 Jun;20(3):268-76
pubmed: 20346647
Biochem Biophys Res Commun. 2013 May 31;435(2):260-6
pubmed: 23639616